Disclaimer

This is a template and must be adapted according to the requirements of the manufacturer/product. This also applies to the corporate design as well as any requirements of the manufacturer's quality management.

All contents of this template are based on the current interpretations of the regulatory requirements.

The pre-entered contents must always be critically reviewed, adapted or supplemented in relation to the product. THIS IS NOT A FILL-IN TEMPLATE ONLY.

Further notes on the application of the template


Yellow markings are to be checked and supplemented or adapted

Yellow marked, italic text parts are optional and have to be checked, supplemented or adapted accordingly

Light blue, italicized text parts are content notes or examples and not part of the document, i.e. they can be deleted after inserting the content into the respective section.

The present page is not part of the document and is to be removed.

Logo manufacturer Risk Analysis Table Revision: x.x Product(s) or trade name(s) / product group/family



P = probability of occurrence; S = severity; R = risk range (h = high, l = low)

Please fill in table with all identified (potential) risks to the production and the device itself and expand for this purpose if necessary.

Disclaimer

This is a template and must be adapted according to the requirements of the manufacturer/product. This also applies to the corporate design as well as any requirements of the manufacturer's quality management.

All contents of this template are based on the current interpretations of the regulatory requirements.

The pre-entered contents must always be critically reviewed, adapted or supplemented in relation to the product. THIS IS NOT A FILL-IN TEMPLATE ONLY.

Further notes on the application of the template

Yellow markings are to be checked and supplemented or adapted

Yellow marked, italic text parts are optional and have to be checked, supplemented or adapted accordingly

Light blue, italicized text parts are content notes or examples and not part of the document, i.e. they can be deleted after inserting the content into the respective section.

If check boxes are listed, an adequate box must be checked.

The present page is not part of the document and is to be removed.

<mark>Logo manufacturer</mark>

Risk Analysis & Risk Management Report

Revision:	v ·
INC VISIOII.	/\.

Product(s) or trade name(s) / product group/family

Releases:

	Date	Name	Signature
Quality manager	YYYY-MM-DD		
Released Management:	YYYY-MM-DD		
Author (just name):			

Document history:

Revision	Date	Description of the change
x.x	YYYY-MM-DD	

Risk Analysis & Risk Management Report

Revision:	v
INCVISIOII.	Λ.

Product(s) or trade name(s) / product group/family

1	Sco	pe	
	This risk analysis and risk management report are applicable to the medical devices listed in the associated risk management plan (Risk Management Plan xxx, dated/version xxx).		
	Oth	er, subject of the risk analysis:	
	Tex	xt box for explanations	
2	Rea	son for risk assessment	
		Design & Development, Phase:	
		Input from PMS activities:	
		Changes in the state of the art:	
		Product modification:	
		Changes in processes after development:	
		Corrective and preventive action:	
		Notifications of incidents and new risks:	
		Other:	
Plea	ise bi	riefly explain reason in the corresponding li	ne of the right column
3	Risk	analysis	
	Ver	weisquelle konnte nicht gefunden werden	he risk management plan (see Section <mark>Fehler!</mark> <mark>.</mark>).
		risk analysis was performed according to: xt box for explanations	

3.1 Risk analysis table

Based on the manufacturing process, product design and intended purpose, any risks were identified that are related to the intended purpose, foreseeable misuse and other characteristics related to product safety.

The potential harms were assigned to the corresponding hazard situations and sources of harm. The most severe potential consequence in the event of harm (severity) was then assessed and the probability of occurrence estimated. With these evaluations, the risk matrix (see associated RM plan) was used to determine the general risk = basic risk.

The result divides the basic risk resulting from the source of harm into the risk ranges: "high" (unacceptable) or "low" (largely acceptable). According to these categories, the type of mitigation measures to be applied (design change/modification in manufacturing, protective feature in the device, protective measures in processes and/or safety information) could be selected. The residual risk resulted from the achieved reduction of the basic risk due to the effect of the mitigation measures.

Risk Analysis & Risk Management Report

Revision: x.x

Product(s) or trade name(s) / product group/family

The verification activities for the implementation of each risk control measure as well as the effectiveness of the measures or corresponding references are shown firstly and continue could.

The

As the second of the measures of the measures of the measure as well as the effectiveness of the measures of the measures

Purchase to view full content of the document

The risk management plan has been implemented appropriately

<mark>Logo manufacturer</mark>

Risk Analysis & Risk Management Report

Revision:	
Revision.	х.х

Product(s) or trade name(s) / product group/family

The overall residual risk has been assessed as acceptable. The final verification of the risk control measures is carried out with this risk management report.

Ice

tio-

Ani

ko

Disclaimer

This is a template and must be adapted according to the requirements of the manufacturer/product. This also applies to the corporate design as well as any requirements of the manufacturer's quality management.

All contents of this template are based on the current interpretations of the regulatory requirements.

The pre-entered contents must always be critically reviewed, adapted or supplemented in relation to the product. THIS IS NOT A FILL-IN TEMPLATE ONLY.

Further notes on the application of the template

Yellow markings are to be checked and supplemented or adapted

Yellow marked, italic text parts are optional and have to be checked, supplemented or adapted accordingly

Light blue, italicized text parts are content notes or examples and not part of the document, i.e. they can be deleted after inserting the content into the respective section.

The present page is not part of the document and is to be removed.

Logo	manu	facturer
Logo	mumu	juctuiei

RM Plan Risk Management Plan

Revision:	v	٦
NEVISIOII.	Λ.	

Product(s) or trade name(s) / product group/family

Releases:

	Date	Name	Signature
Quality manager	YYYY-MM-DD		
Released Management:	YYYY-MM-DD		
Author (just name):			

Document history:

Revision	Date	Description of the change
x.x	YYYY-MM-DD	

Logo	manu	facturer
Logo	mama	Jactarer

RM Plan Risk Management Plan

Revision:	、 、
XEVISIOH.	Χ.

R

Product(s) or trade name(s) / product group/family

1 Scope

This plan is applicable to the following medical devices:

Table 1: Medical devices applicable to the plan

Product(s) or trade name(s) / product group/family				
Item no.	em no. Designation Intended purpose *1 Current life cycle phase *2			

^{*1} The intended purpose should take into account information such as intended medical indication, patient population, part of the body or type of tissue interacted with, user profile, use environment, and operating principle. (EN ISO 14971:2019 +

The risk management plan refers to product risk activities and documentation. The scope of risk management is limited to the medical devices mentioned above, the interface with other devices and the intended purpose stated by the manufacturer.

Responsibilities and authorities 2

Table 2: Responsibilities and authorities

Responsibilities / risk management activities	Function	Assigned person(s)
Release of risk management	Management	
Determine risk management team and team leader (TL).	Management	
Defining acceptance criteria for risk management in line with risk policy	Risk management team	
Risk management plan	Risk management team	
 Risk analysis Description of the intended purpose and reasonably foreseeable misuse Identification of the characteristics that are related to safety Identification of associated hazards and hazardous situations Estimation of risks for each hazardous situation 	Risk management team	
Risk assessment	Risk management team	

 $^{^{*2}}$ z.B. indication of development phase or production and post-production phase.

RM Plan Risk Management Plan Product(s) or trade name(s) / product group/family Revision: x.x

Responsibilities /	

Purchase to view full content of the document

RM Plan Risk Management Plan

Revision: x.x

Product(s) or trade name(s) / product group/family

The results are recorded in the analysis and assessment documents in accordance with the PMS plan and the CAPA forms (in accordance with standard operating procedure xxx). If an

RM Plan Risk Management Plan

Revision: x.x

Product(s) or trade name(s) / product group/family

Table 4: Determination of probability of occurrence (P), qualitative level of probability of occurrence (related to xy times product is used, which is equal to sales of the product per year / which is equal to sales of xy products per year) An explanation applicable to the device should be provided

Common terms		Probability range	
Frequent	A5	> 1 out of 100	$(p > 10^{-2})$
Probable	A4	≤ 1 out of 100	$(p \le 10^{-2})$
Occasional	А3	≤ 1 out of 1000	(p ≤ 10 ⁻⁴)
Remote	A2	≤ 1 out of 10.000	(p ≤ 10 ⁻⁶)
Improbable	A1	≤ 1 out of 100.000	(p ≤ 10 ⁻⁸)

Table 5: Risk matrix, semi-quantitative 5x5 matrix

		Severity				
		S-1	S-2	S-3	S-4	S-5
Occurrence probability	P-5					
	P-4					
	P-3					
	P-2					
ŏ	P-1					

If a probability of occurrence cannot be estimated, a list of possible consequences is drawn up. In determining the probability, the possible harm and the severity of the harm are considered. Information is taken from the following sources, for example:

- published standards
- scientific or technical investigations
- Market data on similar medical devices already in use, including publicly available incident reports
- usability tests with typical users
- clinical evidence
- results of relevant investigations or simulations
- expert reports

After evaluation of the acceptance criteria, the risk under consideration is assigned to either a "high" or "low" risk range (see Table 6).

1. In the "high" range are the unacceptable risks related to the complete risk management process.

RM Plan Risk Management Plan Product(s) or trade name(s) / product group/family Revision: x.x

Notwithstanding point 1, the range "high" can be accepted if the benefit-risk analysis determines that the medical benefit outweighs the remaining risk

RM Plan Risk Management Plan

Revision: x.x

Product(s) or trade name(s) / product group/family

Table 7: Differentiated risk matrix for overall residual risk assessment